Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2020 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting

53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07,...